Annals of internal medicine
-
Multicenter Study
Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis.
Patients with end-stage idiopathic pulmonary fibrosis (IPF) are increasingly having bilateral rather than single-lung transplantation. ⋯ None.
-
Randomized Controlled Trial Multicenter Study
A computerized handheld decision-support system to improve pulmonary embolism diagnosis: a randomized trial.
Testing for pulmonary embolism often differs from that recommended by evidence-based guidelines. ⋯ A handheld decision-support system improved diagnostic decision making for patients with suspected pulmonary embolism in the emergency department.
-
Randomized Controlled Trial Multicenter Study
Two self-management interventions to improve hypertension control: a randomized trial.
Fewer than 40% of persons with hypertension in the United States have adequate blood pressure (BP) control. ⋯ Combined home BP monitoring and tailored behavioral telephone intervention improved BP control, systolic BP, and diastolic BP at 24 months relative to usual care. .
-
Multicenter Study Meta Analysis
Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture.
Osteoporosis is a highly heritable trait. Many candidate genes have been proposed as being involved in regulating bone mineral density (BMD). Few of these findings have been replicated in independent studies. ⋯ In this large-scale collaborative genome-wide meta-analysis, 9 of 150 candidate genes were associated with regulation of BMD, 4 of which also significantly affected risk for fracture. However, most candidate genes had no consistent association with BMD.
-
Randomized Controlled Trial Multicenter Study
Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
Inhaled corticosteroids (ICSs) and long-acting beta(2)-agonists (LABAs) are used to treat moderate to severe chronic obstructive pulmonary disease (COPD). ⋯ ICS therapy decreases inflammation and can attenuate decline in lung function in steroid-naive patients with moderate to severe COPD. Adding LABAs does not enhance these effects. .